for skincare, cosmetics, supplementary food and skin medicine under trademarks including trademark of “DERMALIS”, (which will be transferred on share sale and purchase date from the seller’s connected

established in 2011 and operated business Original Equipment Manufacturer or OEM for skincare, cosmetics, supplementary food and skin medicine under trademarks including trademark of “DERMALIS”, (which will be

skin medicine under trademarks including trademark of “DERMALIS”, (which will be Criterion Calculation Method Transaction size 1. Net tangible assets (NTA) Proportion of assets acquired (100%) x NTA AT

and Drug Administration (CFDA), which took around 2 months, that we have got CFDA in early 2018. Sales by product category Consolidated financial statements For the three months period ended March 31

international sales declined dramatically at 46.03% compared to the same period of the previous year. One of the issues was the delayed product delivery after the license was issued from China Food and Drug

granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change

issued from China Food and Drug Administration (CFDA) at the beginning of 2018 as the Company had to redesign its packaging to comply with the requirements of the license and adjust its sales structures

, e.g., supermarket, food and restaurants (only for takeaway), drug stores.  Online sales continued to grow remarkably by 150.0% YoY.  Gross profit margin from sale of goods improved outstandingly to

baht or 6. 56 percent from the previous year, mainly due to a decrease of drug and medical supply cost since the volume of general patients and social security patients decreased. Besides, the Company

quite a longer process of licenses than expected, e.g., import license and food serial number from the Food and Drug Administration (FDA). In addition, the Company is in the process of adjusting its